LJ10 LLC - 03 Dec 2021 Form 4 Insider Report for Pear Therapeutics, Inc.

Role
Other*
Signature
/s/ Elon Boms Authorized Signatory of LJ10 LLC
Issuer symbol
N/A
Transactions as of
03 Dec 2021
Net transactions value
+$7,520,000
Form type
4
Filing time
06 Dec 2021, 19:30:13 UTC
Next filing
08 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PEARQ Common Stock Conversion of derivative security +6,540,000 6,540,000 03 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Class B Common Stock Conversion of derivative security -6,540,000 -100% 0 03 Dec 2021 Common Stock Direct F1
transaction PEARQ Private Placement Warrants Other $7,520,000 +5,013,333 $1.50* 5,013,333 03 Dec 2021 Common Stock 5,013,333 $11.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

LJ10 LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 In connection with the consummation of the business combination between Thimble Point Acquisition Corp. ("THMA" and the former name of the Issuer) and Pear Therapeutics, Inc. on December 3, 2021 (the "Closing Date"), the Reporting Person's shares of THMA Class B Common Stock were automatically converted into shares of the Issuer's Common Stock on a one-for-one basis.
F2 The private placement warrants were purchased by the Reporting Person in connection with THMA's initial public offering on February 1, 2021. Each private placement warrant is exercisable to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment, beginning on February 4, 2022 and expires on December 3, 2026 or earlier upon redemption or liquidation.

Remarks:

On the Closing Date, the Reporting Person ceased to own more than 10% of a class of the Issuer's equity securities.